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IMPORTANCE Treatments for psoriasis may be less effective in everyday practice than in
clinical trials. Emulating a target trial using data from the British Association of Dermatologists
Biologics and Immunomodulators Register (BADBIR) can provide treatment effect estimates
that are robust and can inform both clinicians and regulatory bodies.
OBJECTIVES To assess the comparative effectiveness of ustekinumab and secukinumab in
patients with psoriasis, and to test whether the relative effectiveness estimate of the CLEAR
trial, a randomized clinical trial that compared secukinumab with ustekinumab for psoriasis,
can be replicated.
DESIGN, SETTING, AND PARTICIPANTS This comparative effectiveness research study used a
target trial emulation approach and was performed between November 2007 and August
2019. Data were obtained from BADBIR, a multicenter longitudinal pharmacovigilance
register of patients with moderate to severe psoriasis in the United Kingdom and Republic of
Ireland. Participants had chronic plaque psoriasis, were 18 years or older, and had at least 1
record of a Psoriasis Area and Severity Index (PASI) of 12 or higher before their initiation to
secukinumab or ustekinumab. Propensity score (PS) 1:1 matched analysis and inverse
probability treatment weighted analysis were performed.
MAIN OUTCOMES AND MEASURES The primary outcomes were the risk ratio (RR) and the risk
difference (RD) for achieving PASI of 2 or lower after 12 months of therapy for secukinumab
compared with ustekinumab. Methods to account for missing outcome data were complete
case analysis, nonresponder imputation, last observation carried forward, inverse probability
of censoring weighting, and multiple imputation. Regulatory and estimate agreement metrics
were used to benchmark the effect estimates in this study against those in the CLEAR trial.
RESULTS A total of 1231 patients were included in the analysis, with 917 receiving ustekinumab
and 314 receiving secukinumab. Secukinumab was superior to ustekinumab in all analyses,
except under the nonresponder imputation method, in the proportion of participants
achieving a PASI of 2 or lower (PS-weighted complete case analysis: RR, 1.28 [95% CI,
1.06-1.55]; RD, 11.9% [1.6-22.1]). All analyses, except for nonresponder imputation, reached
regulatory agreement in both PS-matching and PS-weighted analyses.
CONCLUSIONS AND RELEVANCE This comparative effectiveness study found that secukinumab
resulted in more patients achieving a PASI of 2 or lower after 12 months of therapy compared
with ustekinumab in patients with psoriasis. Target trial emulation in this study resulted in
regulatory and estimate agreement with the CLEAR randomized clinical trial; further such
studies may help fill the evidence gap when comparing other systemic therapies for psoriasis.
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E vidence of the comparative effectiveness of systemictreatments for psoriasis is important to inform the treat-ment choice of patients and clinicians. Randomized
clinical trials (RCTs) that compare 2 agents are the criterion
standard level of evidence for treatment efficacy. However, cur-
rent RCTs in psoriasis have several limitations. First, little in-
centive exists in the pharmaceutical industry to perform head-
to-head studies unless drug manufacturers are confident that
they will be able to demonstrate the superiority of their prod-
uct. Second, evidence of the comparative efficacy of nonbio-
logic systemic therapies is lacking.1 Third, RCTs do not fully
reflect the outcomes observed in real-world settings.2,3 Com-
parative effectiveness studies of systemic therapies for pso-
riasis that use observational data can provide findings to in-
form clinical evidence in the absence of RCT results. Such data
may also help to quantify the efficacy-effectiveness gap, where
efficacy is the performance of treatments under ideal condi-
tions and effectiveness is the performance of treatments in a
clinical setting, between trial and real-world outcomes if trial
data are available.
Comparative effectiveness studies can be affected by sev-
eral sources of bias, including, for example, selection, confound-
ing, and immortal time bias. A method to avoid these biases is
toexplicitlycharacterizeatargettrial (ie, theidealRCTthatwould
be conducted if feasible) to provide a structured approach to
guide the analysis and thereby minimize bias.4-6 This approach
includes outlining the key aspects of the target trial, such as the
eligibility criteria, treatment strategies, assignment procedure,
follow-up period, and causal contrasts of interest, and then
applying this design as much as possible to the observational
data set.
We performed a benchmarking study to compare the
effectiveness of secukinumab (Cosentyx) with that of
ustekinumab (Stelara) using data from the British Associa-
tion of Dermatologists Biologics and Immunomodulators
Register (BADBIR) by emulating a pragmatic RCT. The rel-
evant corresponding RCT was the CLEAR (A 52-week, Multi-
center, Randomized, Double-blind Study of Subcutaneous
Secukinumab to Demonstrate Efficacy as Assessed by Pso-
riasis Area and Severity Index at 16 Weeks of Treatment
Compared to Ustekinumab and to Assess Long-term Safety,
Tolerability and Efficacy in Subjects With Moderate to
Severe Plaque Psoriasis) trial,7,8 a head-to-head comparison
between secukinumab and ustekinumab. Our objective was
to test 2 hypotheses: (1) the real-world effectiveness of both
therapies in BADBIR was lower than that reported in the
CLEAR trial, and (2) the relative effectiveness between the
therapies documented in BADBIR in an emulated pragmatic
RCT would be similar to their relative efficacy in an explana-
tory RCT (CLEAR trial). We used the agreement metrics
described in an article by Franklin et al6 to evaluate whether
we were successful in replicating the relative effect esti-
mates of the CLEAR trial. These metrics were regulatory
agreement, which indicates whether the study replicates
the direction and statistical significance of the RCT findings;
estimate agreement, which indicates whether the study
effect estimate lies within the 95% CI of the effect estimate
in the RCT; and the magnitude and direction of the differ-
ences between the study and RCT results, as measured by
the standardized difference.
Methods
This comparative effectiveness research study was per-
formed between November 2007 and August 2019. BADBIR
was approved in 2007 by the National Health Service Re-
search Ethics Committee North West England. All partici-
pants in the registry gave written informed consent. This ap-
proval extends to the present study. We followed the
Strengthening the Reporting of Observational Studies in Epi-
demiology (STROBE) reporting guideline.
Data Source and Eligibility Criteria
BADBIR is a large registry of patients with moderate to
severe psoriasis in the UK and Republic of Ireland who were
receiving either a traditional systemic therapy, a new oral
small molecule systemic therapy, or a biologic therapy.
Established in September 2007 as a pharmacovigilance reg-
ister, BADBIR contains detailed information on the disease
characteristics, severity, and comorbid conditions of
patients collected at baseline entry into the register. Subse-
quently, data, including disease severity and any adverse
events (AEs), are collected every 6 months for the first 3
years and then annually thereafter. The study design and
baseline characteristics of patients recruited in BADBIR
have been reported in detail.9,10 A data cutoff date of August
2019 was used in the present study. Details of the reference
RCT, the CLEAR trial, are shown in the eAppendix in the
Supplement.
Individuals eligible for the present study had chronic
plaque psoriasis and were 18 years or older. Past use of any
systemic therapy was allowed, with the exception of
ustekinumab, secukinumab, or other biologic therapies that
targeted the interleukin 17 and 23 pathways. Individuals
needed to have at least 1 record of a Psoriasis Area and
Severity Index (PASI) of 12 or higher prior to the initiation of
Key Points
Question What is the effectiveness of secukinumab compared
with ustekinumab for the treatment of psoriasis in an everyday
clinical setting?
Findings In this comparative effectiveness research study of 1231
patients receiving either secukinumab or ustekinumab for
psoriasis, both drugs had lower treatment effectiveness in a
real-world clinical setting than in a trial setting. Secukinumab had
superior effectiveness compared with ustekinumab, and the
estimate of this relative effect using observational data met
regulatory and estimate agreement with trial data.
Meaning Results of this study found a gap between the efficacy
of biologic therapies in an idealized trial setting and the
effectiveness of biologic therapies in the real-world clinical setting
in the treatment of psoriasis; however, a target trial emulation
approach can provide robust estimates of relative effectiveness
that can be used for clinical and regulatory decision-making.
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the biologic under investigation. We restricted the drug ini-
tiation to dates on or after September 2013, when both
secukinumab and ustekinumab were available to patients in
the UK clinical setting, and before September 2018 to allow
individuals time to complete 12 months of treatment. We
placed no exclusions on the basis of comorbid conditions to
maximize external validity.
Treatment Strategies and Follow-up
Partic ipants were receiving either ustekinumab or
secukinumab. Any concomitant topical therapies were al-
lowed, as were concomitant systemic treatments for psoria-
sis, which we adjusted for in the data analysis. Dosing strate-
gies were established by the individual clinicians. Follow-up
for each participant started on the date that ustekinumab or
secukinumab was initiated. Demographic characteristics of
each participant were documented on or before this start date.
Follow-up ended at the occurrence of death, loss to follow-
up, discontinuation of therapy, or 12-month outcome. The rea-
sons for discontinuation of therapy (eg, ineffectiveness, AEs,
or remission) were documented by the clinical research team.
Outcomes
The primary outcome of this study was the difference in the
proportion of participants who achieved a PASI of 2 or lower
after 12 months of therapy between the 2 comparator co-
horts. We performed sensitivity analyses using PASI 90 (ie,
≥90% improvement in PASI) as an alternative secondary out-
come. Justification for choosing these outcomes are pro-
vided in the eAppendix in the Supplement. The AEs and seri-
ous AEs were coded using the Medical Dictionary for
Regulatory Activities (MedDRA) terms and presented in a de-
scriptive analysis.
Statistical Analysis
A propensity score (PS) was fitted using multivariable logistic
regression to account for potential confounding between the
secukinumab and ustekinumab cohorts. Two PS methods were
used: (1) PS nearest-neighbor optimal 1:1 matching with a cali-
per of 0.05 was performed to identify the secukinumab and
ustekinumab cohorts in the first analysis, and (2) inverse prob-
ability treatment weighting was used to balance the 2 cohorts
in the second analysis. Details of the covariates within the PS
and the methods used are described in the eAppendix in the
Supplement.
Only eligible individuals with no missing baseline data for
the potential confounders were included in the study. In the
case of missing outcome data, the outcome was imputed as a
nonresponder after 12 months of treatment if the treatment
was discontinued before that time point because of ineffec-
tiveness or if an AE for psoriasis flare was entered within 1
month of the cessation of therapy. The outcome was imputed
as a responder after 12 months of treatment if the treatment
was discontinued because of disease remission.
To investigate the implication of missing outcome data for
the effect estimate, we used nonresponder imputation (NRI),
last observation carried forward (LOCF), multiple imputa-
tion (MI), and inverse probability of censoring weighting (IPCW)
to account for missing outcome data in the separate analyses
for the intention-to-treat estimate (ie, analysis of partici-
pants according to the original treatment assignment) and the
complete case analysis (CCA) for the per-protocol estimate (ie,
analysis of participants according to the completion of the
assigned treatment). A summary of these methods is pre-
sented in the eAppendix in the Supplement.
Generalized linear models were fitted with a log link for
the relative risk ratio (RR) and an identity link for the risk dif-
ference (RD). Robust SEs were estimated, and matched sets
were accounted for in the PS-matched analysis. We per-
formed a sensitivity analysis to investigate the implication of
weight truncation for the PS-weighted analysis. We used the
aforementioned metrics (ie, regulatory agreement, estimate
agreement, and standardized difference) to benchmark the ef-
fect estimates in this study with those in the CLEAR trial7,8 that
compared the PASI 90 achievement between secukinumab and
ustekinumab.
All data analyses were performed with Stata, version 16.1
(StataCorp LLC).
Results
A total of 1231 patients were included in the analysis, with 917
receiving ustekinumab and 314 receiving secukinumab. Table 1
shows the baseline characteristics of the 2 cohorts, and the pa-
tient flow diagram is presented in eFigure 1 in the Supple-
ment. The PASI at 12 months was recorded for 132 partici-
pants (42.0%) in the secukinumab cohort and 417 participants
(45.5%) in the ustekinumab cohort (eFigure 1 in the
Supplement).
The numbers of participants in each cohort who experi-
enced AEs and serious AEs are presented in eTable 1 in the
Supplement, with few serious AEs reported within 12 months
in both cohorts. Fewer than 5 AEs in the secukinumab and
ustekinumab cohorts were coded with the MedDRA high-
level term of fungal infection disorders. No AEs in the
secukinumab cohort and 5 AEs in the ustekinumab cohort were
coded with MedDRA high-level term of noninfective colitis.
The PS matching analysis included 622 participants, with
311 participants in each treatment cohort (eFigure 2 in the
Supplement). Weight truncation did not improve the preci-
sion of the estimate materially and therefore was not imple-
mented (eTable 2 in the Supplement). Both PS matching and
PS weighting methods resulted in 2 balanced cohorts (eTables 3
and 4 in the Supplement).
The RRs (Figure) and RDs (eFigure 3 in the Supplement)
that compared the proportion of participants who achieved a
PASI of 2 or lower at 12 months in the secukinumab and
ustekinumab cohorts, estimated from the generalized linear
models using the missing outcome imputation methods, are
presented in Table 2. Table 2 also shows the corresponding out-
come measures from the CLEAR trial. The proportion of par-
ticipants who achieved the outcome was lower in this study,
regardless of the methods used for confounding adjustment
or outcome imputation, compared with the CLEAR trial
(Table 2).
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All methods to account for missing outcome data,
except NRI in the PS weighting, reached regulatory agree-
ment for RRs and RDs (Table 2). However, a discrepancy
was found regarding which method achieved estimate
agreement. All methods achieved estimate agreement in the
PS-weighted analysis, except for NRI for RD (Table 2). In
contrast, CCA (RR, 1.55; 95% CI, 1.19-2.01), NRI (RR, 1.45;
95% CI, 1.04-2.03), IPCW (RR, 1.50; 95% CI, 1.14- 1.96), and
MI (RR, 1.44; 95% CI, 1.07-1.94) all overestimated the RR in
the PS-matched analysis, violating estimate agreement. The
PS-matched analysis performed better in estimation of RD,
reaching estimate agreement for all missing outcome impu-
tation methods (CCA: 19.5% [95% CI, 0.1%-31.6%]; NRI:
7.2% [95% CI, 0.4%-13.9%]; IPCW: 18.3% [95% CI, 5.5%-
31.1%]; LOCF: 14.0% [95% CI, 5.9%-22.1%]; MI: 16.9% [95%
CI, 3.3%-30.6%]) (Table 2). The method that resulted in the
lowest standardized difference for RR and RD between this
study and the CLEAR trial was LOCF with PS matching (RR,
0.009; RD, −0.003). Secukinumab was superior to
ustekinumab in all analyses, except under the nonre-
sponder imputation method, in the proportion of partici-
pants achieving a PASI of 2 or lower (PS-weighted complete
case analysis: RR, 1.28 [95% CI, 1.06-1.55]; RD, 11.9% [1.6-
22.1]). The PS-weighted sensitivity analysis using PASI 90 as
an alternative outcome gave similar results (eTable 5 in the
Supplement).
Discussion
To our knowledge, this study was the first to use a target trial
approach in comparative effectiveness research of systemic
therapies for psoriasis. Using this method, we showed that a
robust analysis of data from BADBIR can yield comparative
treatment effect estimates that replicate the estimates re-
ported in an RCT and therefore can be reliable for clinical de-
cision-making.
We found that NRI was not an appropriate missing out-
come analysis method for the observational data. Using NRI was
overly conservative and introduced nondifferential misclassi-
fication that biased the effect estimate toward the null and un-
derestimated the effect size for each treatment cohort. The LOCF
method produced the most precise results, but its estimate was
Table 1. Baseline Characteristics of the Ustekinumab
and Secukinumab Cohorts
Characteristic
No. (%)
Ustekinumab
cohort
(n = 917)
Secukinumab
cohort
(n = 314)
Age, median (IQR), y 45.0
(35.0-55.0)
46.0
(36.0-55.0)
Female sex 365 (39.8) 121 (38.5)
BMI 30.9
(26.6-36.5)
30.5
(26.7-35.1)
Weight, median (IQR), kg 92.0
(77.2-107.5)
89.4
(76.4-107.0)
Alcohol
No documented alcohol intake 338 (36.9) 115 (36.6)
Lower-risk drinking (male: <21 U/wk;
female: <14 U/wk)
470 (51.3) 160 (51.0)
Hazardous drinking (male: <50 U/wk;
female: <35 U/wk)
96 (10.5) 36 (11.5)
Harmful drinking (male: ≥50 U/wk;
female: ≥35 U/wk)
13 (1.4) 3 (1.0)
Smoking status
Never 320 (34.9) 126 (40.1)
Previous 346 (37.7) 109 (34.7)
Current 251 (27.4) 79 (25.2)
Baseline PASI 16.3
(13.9-21.1)
17.6
(14.4-22.7)
Psoriatic arthritis 135 (14.7) 64 (20.4)
No. of previous biologic therapies
None 770 (84.0) 261 (83.1)
1 103 (11.2) 33 (10.5)
2 33 (3.6) 16 (5.1)
≥3 11 (1.2) 4 (1.3)
No. of previous conventional therapies
None 72 (7.9) 30 (9.6)
1 209 (22.8) 88 (28.0)
2 302 (32.9) 120 (38.2)
≥3 334 (36.4) 76 (24.2)
Previously treated with TNF inhibitors 144 (15.7) 50 (15.9)
Treated with a concomitant systemic
therapy
118 (12.9) 15 (4.8)
No. of comorbid conditions
None 262 (28.6) 108 (34.4)
1-2 463 (50.5) 152 (48.4)
3-4 152 (16.6) 45 (14.3)
≥5 40 (4.4) 9 (2.9)
Psoriasis
Palmoplantar 189 (20.6) 58 (18.5)
Nail 488 (53.2) 174 (55.4)
Scalp 690 (75.2) 234 (74.5)
Depression 227 (24.8) 62 (19.7)
Working status
Full-time 493 (53.8) 191 (60.8)
Part-time 111 (12.1) 35 (11.1)
Full-time in the home 30 (3.3) 13 (4.1)
Unemployed but seeking work 39 (4.3) 11 (3.5)
Not working because of disability/ill
health
117 (12.8) 28 (8.9)
Student 22 (2.4) 6 (1.9)
Retired 105 (11.5) 30 (9.6)
(continued)
Table 1. Baseline Characteristics of the Ustekinumab
and Secukinumab Cohorts (continued)
Characteristic
No. (%)
Ustekinumab
cohort
(n = 917)
Secukinumab
cohort
(n = 314)
Race/ethnicity
White 816 (89.0) 289 (92.0)
Black 9 (1.0) 0
Asian 54 (5.9) 14 (4.5)
Other 38 (4.1) 11 (3.5)
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided
by height in meters squared); IQR, interquartile range; PASI, Psoriasis Area and
Severity Index; TNF, tumor necrosis factor.
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less accurate when using PS weighting than the corresponding
estimate in the CLEAR trial, shifting the effect estimate slightly
toward the null. In addition, single imputation methods such as
NRI and LOCF lead to an underestimation of SEs and uncer-
tainty and may increase the likelihood of finding a false-
positive result.11 We found that CCA, MI, and IPCW generated
similar effect estimates and width of CIs using PS weighting.
Insights for Clinical Practice
Taking the point estimate from CCA under PS weighting, we
observed a 17.5% reduction for secukinumab and 15.1% reduc-
tion for ustekinumab between efficacy and effectiveness using
the 12-month end point (Table 2). Patients and clinicians
should, therefore, be informed that the probability of achiev-
ing a PASI of 2 or lower or PASI 90 was lower for both
secukinumab and ustekinumab cohorts in the real world than
the odds reported in the CLEAR trial, and secukinumab had
statistic ally superior effectiveness compared with
ustekinumab. When counseling patients about the likely out-
come of biologic therapies on the basis of figures from clini-
cal trials, clinicians should include a caveat that the real-
world outcome may be around 15% lower than that found in
clinical trials.
We have shown that the target trial method using obser-
vational data can lead to robust treatment effect estimates for
psoriasis. As a result, we believe that clinicians can interpret
other or future comparative effectiveness studies with a tar-
get trial framework with confidence and use this information
in shared decision-making as an adjunct to data from RCTs.
Previous studies have shown that drug survival of
secukinumab is similar to that of ustekinumab at year 1 when
only the discontinuation because of ineffectiveness is taken
into account.12 Thus, the results of this study suggest that drug
survival alone cannot be a sensitive proxy for effectiveness.13
Assumptions
An important bias to consider is that knowledge of the find-
ings from the corresponding CLEAR trial may have altered
the current study. To further test the robustness of this pro-
cess, the method should be repeated using BADBIR data to
conduct a comparative effectiveness study of drugs with
corresponding, ongoing RCTs. Similar to other benchmark-
ing studies, this study assumed that trial participation had
no direct impact and that no unmeasured confounding was
associated with the impact of trial participation.14
There are 2 assumptions with PS methods in observa-
tional data. The first is the strong ignorability of sample
selection assumption, which assumes that no unobserved
confounding leads to the differences in the distribution of
potential outcomes for the 2 treatments.15 This assumption
is unlikely to be completely true, but given that the effect
estimate in this study closely replicated that in the CLEAR
trial, it is unlikely that any unmeasured confounding has
important implications. The second assumption is the
stable unit treatment value assumption, which assumes that
the treatment has the same implication for an individual
regardless of how the individual came to be treated and that
the implication of the treatment for the individual is inde-
pendent of the treatment of other individuals.16 This
assumption is associated with whether the study results can
be generalized beyond the study population, and our ability
to replicate the RR from the CLEAR trial suggests that this
second assumption may also hold true.
This calibration study is a first step in demonstrating
that real-world evidence can be analyzed in a way that tests
other hypotheses of the comparative effectiveness of pso-
riasis treatments. We encourage researchers to test the
robustness of this approach by conducting benchmarking
replication studies using other psoriasis registries and a tar-
get trial framework. Although this approach cannot and
should not take the place of the criterion standard of head-
to-head biologics RCT, it has the potential to further such
trials and may help fill the comparative effectiveness gap for
systemic treatments of psoriasis. Such replication studies
may provide more timely but similarly robust information
to inform clinical decision-making.
Figure. Forest Plot of the Risk Ratio (RR) Estimates for Participants Achieving Psoriasis Area
and Severity Index of 2 or Lower at 12 Months
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Strengths and Limitations
We were able to perform this study because of the detailed base-
line participant data captured in BADBIR, including important
covariates from demographic data, disease severity, and spe-
cific site involvement, comorbid conditions, and concomitant
treatments. Having such data allowed us to balance the 2 co-
horts to minimize confounding. The target trial approach also
necessitated a new user active-comparator study design, a ro-
bust design that leads to balanced patient baseline covariates be-
tween 2 treatment comparators.17 Unlike analyses that used rou-
tinely collected health care or insurance claims data, the present
study faced little potential misclassification in the diagnosis of
psoriasis and the specific biologic therapy the patient received.
This analysis would not be possible if we used routinely col-
lected health care or insurance claims data because their sources
generally do not record disease severity along with commence-
ment or subsequent claims of a drug.
The main limitation pertains to the amount of missing out-
come data, with approximately 45% of the cohort having a re-
corded PASI at 12 months available for analysis (eFigures 1 and
2 in the Supplement). We believe that it is reassuring that the CCA
and the MI analyses in the PS-weighted analysis using the en-
Table 2. Outcome of Absolute PASI of 2 or Lower at 12 Months for Secukinumab and Ustekinumaba
Data source and missing outcome
analysis method CLEAR trial NRIb
Present BADBIR study
CCA (n = 265 PS
matched; n = 549
PS weighted) NRI
LOCF (n = 559 PS
matched; n = 1106
PS weighted) IPCW MI
PS-matched analysis (n = 622)
Estimated proportion on
secukinumab achieving
PASI ≤2, % (95% CI)
74.9 59.8 (31.5 to
75.6)
24.7 (19.9 to
29.5)
68.6 (63.2 to
74.1)
60.3 (51.1 to
69.5)
59.6 (51.8 to
67.4)
Estimated proportion on
ustekinumab achieving
PASI ≤2, % (95% CI)
60.6 40.4 (21.8 to
64.2)
17.5 (13.0 to
22.0)
54.7 (48.4 to
61.0)
42.0 (32.7 to
51.3)
42.7 (32.3 to
53.0)
RR (95% CI) 1.24 (1.11 to
1.37)
1.55 (1.19 to
2.01)
1.45 (1.04 to
2.03)
1.26 (1.10 to
1.45)
1.50 (1.14 to
1.96)
1.44 (1.07 to
1.94)
Standardized difference
between CLEAR and BADBIR
studies for RRc
NA 0.048 0.028 0.009 0.040 0.030
RD, % (95% CI) 14.3 (7.2 to
21.1)
19.5 (0.1 to
31.6)
7.2 (0.4 to
13.9)
14.0 (5.9 to
22.1)
18.3 (5.5 to
31.1)
16.9 (3.3 to
30.6)
Standardized difference
between CLEAR and BADBIR
studies for RDc
NA 0.024 −0.047 −0.003 0.018 0.011
PS-weighted analysis (n = 1231)
Estimated proportion on
secukinumab achieving
PASI ≤2, % (95% CI)
74.9 57.4 (48.3 to
66.4)
23.4 (18.5 to
28.2)
67.7 (62.0 to
73.4)
58.2 (48.5 to
67.9)
57.8 (48.5 to
67.1)
Estimated proportion on
ustekinumab achieving
PASI ≤2, % (95% CI)
60.6 45.5 (40.4 to
50.6)
20.4 (17.6 to
23.2)
58.6 (55.0 to
62.2)
45.9 (40.7 to
51.1)
44.7 (39.5 to
49.9)
RR (95% CI) 1.24 (1.11 to
1.37)
1.28 (1.06 to
1.55)
1.16 (0.91 to
1.48)
1.16 (1.04 to
1.29)
1.29 (1.06 to
1.58)
1.30 (1.04 to
1.62)
Standardized difference
between CLEAR and BADBIR
studies for RRc
NA 0.012 −0.016 −0.030 0.013 0.013
RD, % (95% CI) 14.3 (7.2 to
21.1)
11.9 (1.6 to
22.1)
2.9 (−2.6 to
8.5)
9.1 (2.4 to
15.8)
12.3 (1.4 to
23.2)
13.1 (1.3 to
24.9)
Standardized difference
between CLEAR and BADBIR
studies for RDc
NA −0.012 −0.081 −0.034 −0.010 −0.006
Regulatory agreementd NA Yes Yes (matched);
No (weighted)
Yes Yes Yes
Estimate agreemente NA Yes (weighted);
No (matched)
RR: yes
(weighted);
no (matched)
RD: yes (matched);
no (weighted)
Yes RR: yes
(weighted); no
(matched)
RD: yes
RR: yes
(weighted);
No (matched)
RD: yes
Abbreviations: BADBIR, British Association of Dermatologists Biologics and
Immunomodulators Register; CCA, complete case analysis; IPCW, inverse
probability of censoring weighting; LOCF, last observation carried forward; MI,
multiple imputation; NA, not applicable; NRI, nonresponder imputation; PASI,
Psoriasis Area and Severity Index; PS, propensity score; RCT, randomized clinical
trial; RD, risk difference; RR, risk ratio.
a RR and RD were calculated using MedCalc.net.
b Numbers from the PASI 90 nonresponder imputation outcome at week 52 in
the CLEAR study.7,8
c Standardized difference was calculated according to the methods in Franklin
et al.6
d Indicates whether the study replicates the direction and statistical significance
of the CLEAR study7,8 finding.
e Indicates whether the study treatment effect is within the 95% CI of the
treatment effect estimate from the CLEAR study.7,8
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tire cohort, which estimated the mean treatment effect in the
whole population, gave RRs similar to those in the CLEAR RCT.
This finding suggests that this missing mechanism of PASI at 12
months was either missing completely at random or missing at
random; both situations can be accounted for using the analy-
ses in this study. The other possibility was that the PASI was miss-
ing not at random but was missing similarly in both treatment
cohorts and thus not exerting a substantial differential implica-
tion for the estimate of relative treatment effect. Because BAD-
BIR does not require recording of data at 16 weeks, we were un-
able to use the primary end point of PASI 90 at week 16 in the
CLEAR trial as the benchmark effect estimate. Although the AEs
were reported herein for completeness, the comparative safety
ofsecukinumabandustekinumabshouldnotbeinterpretedfrom
this analysis; rather, an analysis that considers the potential con-
founders specific to the AE should be undertaken in a larger
cohort.
Conclusions
In this comparative effectiveness research study, treatment
with secukinumab resulted in a higher proportion of patients
reaching a PASI of 2 or lower after 12 months of therapy com-
pared with the ustekinumab cohort in the BADBIR popula-
tion, but an efficacy-effectiveness gap was found for both treat-
ments. A target trial emulation approach can be used to perform
comparative effectiveness studies in BADBIR with a high de-
gree of agreement with a corresponding RCT for relative ef-
fectiveness of therapies for psoriasis. We suggest the use of this
target trial framework in future comparative effectiveness stud-
ies that use data from BADBIR. Such research also should con-
sider using PS weighting for confounding adjustment and either
the CCA, MI, or IPCW method for imputing missing outcome
data.
ARTICLE INFORMATION
Accepted for Publication: September 6, 2020.
Published Online: December 2, 2020.
doi:10.1001/jamadermatol.2020.4202
Open Access: This is an open access article
distributed under the terms of the CC-BY License.
© 2020 Yiu ZZN et al. JAMA Dermatology.
Author Affiliations: Centre for Dermatology
Research, Salford Royal NHS Foundation Trust, The
University of Manchester, Manchester Academic
Health Science Centre, National Institute for Health
Research (NIHR) Manchester Biomedical Research
Centre, Manchester, United Kingdom (Yiu, Mason,
Griffiths, Warren); Institute of Translational and
Clinical Medicine, Newcastle University Medical
School, Newcastle upon Tyne, United Kingdom
(Hampton, Reynolds); Department of Dermatology,
Royal Victoria Infirmary and NIHR Newcastle
Biomedical Research Centre, Newcastle Hospitals
NHS Foundation Trust, Newcastle upon Tyne,
United Kingdom (Hampton, Reynolds); St John’s
Institute of Dermatology, Guy’s and St Thomas’ NHS
Foundation Trust, London, United Kingdom
(Smith); Versus Arthritis Centre for Epidemiology,
The University of Manchester, Manchester,
United Kingdom (Lunt).
Author Contributions: Dr Yiu had full access to all
of the data in the study and takes responsibility for
the integrity of the data and the accuracy of the
data analysis.
Concept and design: Yiu, Lunt, Griffiths, Warren.
Acquisition, analysis, or interpretation of data:
All authors.
Drafting of the manuscript: Yiu, Mason.
Critical revision of the manuscript for important
intellectual content: All authors.
Statistical analysis: Yiu, Lunt.
Obtained funding: Yiu, Griffiths, Warren.
Administrative, technical, or material support: Lunt.
Supervision: Smith, Lunt, Griffiths, Warren.
Conflict of Interest Disclosures: Dr Mason
reported receiving personal fees from Janssen, LEO
Pharma, Lilly, and Novartis outside the submitted
work. Dr Reynolds reported receiving lecture fees
from AbbVie, Almirall, Celgene, Janssen, and UCB
Pharma Ltd outside the submitted work; receiving
grants from and serving on the medical advisory
board of Novartis; serving on the medical advisory
board of Almirall; institutional support form
AnaptysBio; and being a National Institute for
Health Research (NIHR) senior investigator. Dr
Smith reported receiving other from AbbVie,
Novartis, Pfizer, Sanofi, Boehringer Ingelheim, and
Sobi; grants from a Medical Research Council–
funded stratified medicine consortium with
multiple industry partners; and grants from IMI
(Horizon 2020)-funded European consortium with
multiple industry partners during the conduct of
the study. Dr Griffiths reported receiving grants
from AbbVie, Almirall, and Amgen; personal fees
from Bristol Myers Squibb; and grants and personal
fees from Janssen, LEO Pharma, Lilly, Novartis,
Sandoz, and UCB Pharma Ltd during the conduct of
the study as well as being an NIHR emeritus senior
investigator. Dr Warren reported receiving grants
from AbbVie, Almirall, Amgen, Celgene, Janssen,
Lilly, LEO Pharma, Novartis, Pfizer, and UCB Pharma
Ltd during the conduct of the study, as well as
personal fees from AbbVie, Almirall, Amgen, Arena,
Avillion, Bristol Myers Squibb, Boehringer
Ingelheim, Celgene, Janssen, LEO Pharma, Lilly,
Novartis, Pfizer, Sanofi, and UCB Pharma Ltd
outside the submitted work. No other disclosures
were reported.
Funding/Support: This research was supported in
part by the NIHR Manchester Biomedical Research
Centre and the NIHR Newcastle Biomedical
Research Centre. Dr Yiu was funded by an NIHR
Academic Clinical Lectureship through The
University of Manchester. Drs Griffiths and Warren
were funded in part by grant MR/L011808/1 from
the Medical Research Council. The study group
British Association of Dermatologists Biologics and
Immunomodulators Register (BADBIR) is
coordinated by The University of Manchester and
funded by the British Association of Dermatologists
(BAD). The BAD receives income from AbbVie,
Almirall, Amgen, Celgene, Janssen, LEO Pharma,
Lilly, Novartis, Samsung Bioepis, Sandoz Hexal AG,
and UCB Pharma Ltd for providing
pharmacovigilance services. This income finances a
separate contract between the BAD and The
University of Manchester that coordinate BADBIR.
BADBIR acknowledges the support of the NIHR
through the clinical research networks and the
contribution made by clinical research associates
who continue to facilitate recruitment into the
registry.
Role of the Funder/Sponsor: All decisions
concerning analysis, interpretation, and publication
are made independently of any industry
contribution. All relevant information regarding
serious adverse events mentioned in this
publication has been reported to the appropriate
company as per the contractual agreements/
standard operating procedures. The funders had no
role in the design and conduct of the study;
collection, management, analysis, and
interpretation of the data; preparation, review, or
approval of the manuscript; and decision to submit
the manuscript for publication.
The BADBIR Study Group: Jonathan N. W. N.
Barker, MD (King’s College London); Marilyn
Benham (British Association of Dermatologists);
Fiona Browne, MB, BCh (Crumlin Children’s
Hospital); A. David Burden, MD (University of
Glasgow); Ian Evans, MSc (The University of
Manchester); Christopher E. M. Griffiths, MD (The
University of Manchester); Sagair Hussain, PhD
(British Association of Dermatologists); Brian Kirby,
MD (St Vincent’s University Hospital); C. Elise
Kleyn, MD (The University of Manchester); Philip
Laws, MBChB (The Leeds Teaching Hospitals NHS
Trust); Linda Lawson, MSc (Aberdeen University);
Kayleigh J. Mason, PhD (The University of
Manchester); Kathleen McElhone, PhD (The
University of Manchester); Teena Mackenzie, RN,
BSc (Oxford University Hospitals); Tess McPherson,
MD (University of Oxford); Ruth Murphy, PhD
(Nottingham University Hospitals); Anthony
Ormerod, MD (Aberdeen University); Caroline
Owen, MD (East Lancashire Hospital NHS Trust);
Eleanor Pearson (Norfolk & Norwich University
Hospitals NHS Foundation Trust); Nick J. Reynolds,
MD (Newcastle University); Josh Richards, PhD
(Patient Representative); Catherine H. Smith, MD
(King’s College London); and Richard B. Warren,
PhD (The University of Manchester).
Disclaimer: The views expressed herein are those
of the authors and do not reflect the official policy
or position of the NHS, the NIHR, or the
Department of Health.
Additional Contributions: We thank all of the
patient participants in BADBIR, without whom we
would not be able to carry out the project. The
substantial contribution of the BADBIR team to the
administration of the project has been vital, and we
Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis Original Investigation Research
jamadermatology.com (Reprinted) JAMA Dermatology Published online December 2, 2020 E7
Downloaded From: https://jamanetwork.com/ on 12/10/2020
especially acknowledge the pharmacovigilance
team for their tireless work: Kathleen McElhone,
PhD; Shamila Irshad, BSc; Victoria Wilde, BSc; and
Saliha Tahir, BSc. We thank Sagair Hussain, PhD, for
his support as the clinical project manager of
BADBIR. We are grateful to the members of the
Data Monitoring Committee (Robert Chalmers,
MBChB; Carsten Flohr, PhD, chair; David
Prieto-Merino, PhD; and Richard Weller, MD) and
the BADBIR Steering Committee (Jonathan Barker,
MD; Marilyn Benham, CEO of BAD; David Burden,
MD, chair; Christopher Griffiths, MD, chief
investigator; Ian Evans, BSc; Sagair Hussain, PhD;
Brian Kirby, MD; Linda Lawson; Kathleen McElhone,
PhD; Tess Macpherson, PhD; Kayleigh Mason, PhD;
Ruth Murphy, PhD; Anthony Ormerod, MD;
Caroline Owen, MBChB; Nick Reynolds, MD, chair of
Research Committee; Catherine Smith, MD; and
Richard Warren, PhD). These individuals received
no additional compensation, outside of their usual
salary, for their contributions. We acknowledge the
enthusiastic collaboration of all of the
dermatologists and specialist nurses in the United
Kingdom and the Republic of Ireland who provided
the data.
REFERENCES
1. Sbidian E, Chaimani A, Afach S, et al. Systemic
pharmacological treatments for chronic plaque
psoriasis: a network meta-analysis. Cochrane
Database Syst Rev. 2020;1:CD011535. doi:10.1002/
14651858.CD011535.pub3
2. Mason KJ, Barker JNWN, Smith CH, et al;
BADBIR Study Group. Comparison of drug
discontinuation, effectiveness, and safety between
clinical trial eligible and ineligible patients in
BADBIR. JAMA Dermatol. 2018;154(5):581-588. doi:
10.1001/jamadermatol.2018.0183
3. Yiu ZZN, Mason KJ, Barker JNWN, et al; BADBIR
Study Group. A standardization approach to
compare treatment safety and effectiveness
outcomes between clinical trials and real-world
populations in psoriasis. Br J Dermatol. 2019;181(6):
1265-1271. doi:10.1111/bjd.17849
4. Hernán MA, Robins JM. Using big data to
emulate a target trial when a randomized trial is not
available. Am J Epidemiol. 2016;183(8):758-764.
doi:10.1093/aje/kwv254
5. Franklin JM, Schneeweiss S. When and how can
real world data analyses substitute for randomized
controlled trials? Clin Pharmacol Ther. 2017;102
(6):924-933. doi:10.1002/cpt.857
6. Franklin JM, Pawar A, Martin D, et al.
Nonrandomized real-world evidence to support
regulatory decision making: process for a
randomized trial replication project. Clin Pharmacol
Ther. 2020;107(4):817-826. doi:10.1002/cpt.1633
7. Thaçi D, Blauvelt A, Reich K, et al. Secukinumab
is superior to ustekinumab in clearing skin of
subjects with moderate to severe plaque psoriasis:
CLEAR, a randomized controlled trial. J Am Acad
Dermatol. 2015;73(3):400-409. doi:10.1016/j.jaad.
2015.05.013
8. Blauvelt A, Reich K, Tsai TF, et al. Secukinumab is
superior to ustekinumab in clearing skin of subjects
with moderate-to-severe plaque psoriasis up to 1
year: results from the CLEAR study. J Am Acad
Dermatol. 2017;76(1):60-69.e9. doi:10.1016/j.jaad.
2016.08.008
9. Iskandar IY, Ashcroft DM, Warren RB, et al.
Demographics and disease characteristics of
patients with psoriasis enrolled in the British
Association of Dermatologists Biologic
Interventions Register. Br J Dermatol. 2015;173(2):
510-518. doi:10.1111/bjd.13908
10. Burden AD, Warren RB, Kleyn CE, et al; BADBIR
Study Group. The British Association of
Dermatologists’ Biologic Interventions Register
(BADBIR): design, methodology and objectives. Br J
Dermatol. 2012;166(3):545-554. doi:10.1111/j.1365-
2133.2012.10835.x
11. Mavridis D, Salanti G, Furukawa TA, Cipriani A,
Chaimani A, White IR. Allowing for uncertainty due
to missing and LOCF imputed outcomes in
meta-analysis. Stat Med. 2019;38(5):720-737. doi:
10.1002/sim.8009
12. Yiu ZZN, Mason KJ, Hampton PJ, et al; BADBIR
Study Group. Drug survival of adalimumab,
ustekinumab and secukinumab in patients with
psoriasis: a prospective cohort study from the
British Association of Dermatologists Biologics and
Immunomodulators Register (BADBIR). Br J Dermatol.
2020;183(2):294-302. doi:10.1111/bjd.18981
13. Dávila-Seijo P, García-Doval I. Drug survival
analysis is not a good method for assessing the
safety or effectiveness of systemic therapies in
psoriasis. Actas Dermosifiliogr. 2017;108(1):3-5.
doi:10.1016/j.adengl.2016.11.001
14. Dahabreh IJ, Robins JM, Hernán MA.
Benchmarking observational methods by
comparing randomized trials and their emulations.
Epidemiology. 2020;31(5):614-619. doi:10.1097/EDE.
0000000000001231
15. Jo B, Stuart EA. On the use of propensity scores
in principal causal effect estimation. Stat Med.
2009;28(23):2857-2875. doi:10.1002/sim.3669
16. Schwartz S, Gatto NM, Campbell UB. Extending
the sufficient component cause model to describe
the Stable Unit Treatment Value Assumption
(SUTVA). Epidemiol Perspect Innov. 2012;9:3.
doi:10.1186/1742-5573-9-3
17. Schneeweiss S, Patrick AR, Stürmer T, et al.
Increasing levels of restriction in pharmacoepide-
miologic database studies of elderly and
comparison with randomized trial results. Med Care.
2007;45(10)(suppl 2):S131-S142. doi:10.1097/MLR.
0b013e318070c08e
Research Original Investigation Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis
E8 JAMA Dermatology Published online December 2, 2020 (Reprinted) jamadermatology.com
Downloaded From: https://jamanetwork.com/ on 12/10/2020
